MaxCyte Appoints Cynthia Collins to its Board of Directors
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) has appointed Cynthia Collins to its Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee, increasing the total Board of Directors to 10 members. With over 40 years of experience in biotechnology and cell and gene medicines, Collins brings valuable expertise to MaxCyte. Her most recent role was as CEO of Editas Medicine, where she was involved in dosing the first patient with an in-vivo gene modified therapy. Collins has also held CEO positions at Human Longevity Inc., GE Healthcare's Cell Therapy and Lab Businesses, and GenVec, Inc. She currently serves on the boards of several healthcare companies and holds a BS in Microbiology from the University of Illinois and an MBA from The University of Chicago Booth School of Business.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) ha nominato Cynthia Collins nel suo Consiglio di Amministrazione come direttore non esecutivo, con effetto dal 14 ottobre 2024. Collins farà parte del comitato per la compensazione del consiglio, portando il totale dei membri del Consiglio di Amministrazione a 10. Con oltre 40 anni di esperienza nella biotecnologia e nelle medicine cellulari e geniche, Collins porta un'esperienza preziosa a MaxCyte. Il suo ruolo più recente è stato CEO di Editas Medicine, dove è stata coinvolta nella somministrazione della prima terapia genica modificata in vivo. Collins ha anche ricoperto posizioni di CEO presso Human Longevity Inc., le attività di Cell Therapy e Lab di GE Healthcare e GenVec, Inc. Attualmente è membro dei consigli di amministrazione di diverse aziende sanitarie e ha conseguito una laurea in Microbiologia presso l'Università dell'Illinois e un MBA presso la Booth School of Business dell'Università di Chicago.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) ha nombrado a Cynthia Collins en su Junta Directiva como directora no ejecutiva, con efecto a partir del 14 de octubre de 2024. Collins formará parte del comité de compensación de la junta, aumentando el total de miembros de la Junta Directiva a 10. Con más de 40 años de experiencia en biotecnología y medicamentos celulares y genéticos, Collins aporta valiosa experiencia a MaxCyte. Su cargo más reciente fue como CEO de Editas Medicine, donde estuvo involucrada en la dosificación del primer paciente con una terapia genética modificada in vivo. Collins también ha ocupado puestos de CEO en Human Longevity Inc., en los negocios de Terapia Celular y Laboratorios de GE Healthcare, y en GenVec, Inc. Actualmente, forma parte de las juntas de varias empresas del sector salud y posee una licenciatura en Microbiología de la Universidad de Illinois y un MBA de la Booth School of Business de la Universidad de Chicago.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT)는 비상임 이사로 Cynthia Collins를 이사회의 일원으로 임명했습니다, 2024년 10월 14일부터 발효됩니다. Collins는 이사회의 보상 위원회에서 활동하며 전체 이사 수를 10명으로 늘립니다. 생명공학 및 세포 유전자 의학 분야에서 40년 이상의 경력을 보유한 Collins는 MaxCyte에 귀중한 전문 지식을 제공합니다. 그녀의 최근 직책은 Editas Medicine의 CEO로, 여기서 그녀는 최초의 환자에게 인비보 유전자 수정 요법을 투여하는 데 참여했습니다. Collins는 Human Longevity Inc., GE Healthcare의 세포 치료 및 실험실 비즈니스, GenVec, Inc.에서도 CEO직을 역임한 바 있습니다. 현재 그녀는 여러 건강 관리 회사의 이사로 활동하며 일리노이 대학에서 미생물학 학사 학위, 시카고 대학교 부스 경영대학원에서 MBA를 취득했습니다.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) a nommé Cynthia Collins au sein de son Conseil d'Administration en tant que directrice non exécutive, avec effet à partir du 14 octobre 2024. Collins siègera au comité de rémunération du conseil, portant le total des membres du Conseil d'Administration à 10. Forte de plus de 40 ans d'expérience dans la biotechnologie ainsi que dans les médicaments cellulaires et géniques, Collins apporte une expertise précieuse à MaxCyte. Son dernier poste était celui de PDG d'Editas Medicine, où elle a été impliquée dans la dosification du premier patient avec une thérapie génique modifiée in vivo. Collins a également occupé des postes de PDG chez Human Longevity Inc., dans les activités de thérapie cellulaire et de laboratoire de GE Healthcare, ainsi que chez GenVec, Inc. Elle siège actuellement aux conseils d'administration de plusieurs entreprises de santé et détient un BS en microbiologie de l'University of Illinois ainsi qu'un MBA de la Booth School of Business de l'University of Chicago.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) hat Cynthia Collins in seinen Aufsichtsrat berufen als nicht-executive Direktorin, wirksam ab dem 14. Oktober 2024. Collins wird im Vergütungsausschuss des Aufsichtsrats tätig werden, wodurch sich die Gesamtzahl der Mitglieder des Aufsichtsrats auf 10 erhöht. Mit über 40 Jahren Erfahrung in der Biotechnologie sowie in Zell- und Gentherapien bringt Collins wertvolle Expertise zu MaxCyte. Ihre zuletzt ausgeübte Rolle war als CEO von Editas Medicine, wo sie bei der Dosierung des ersten Patienten mit einer in-vivo-genmodifizierten Therapie beteiligt war. Collins hatte auch CEO-Positionen bei Human Longevity Inc., den Geschäftsfeldern Zelltherapie und Labore von GE Healthcare sowie GenVec, Inc. inne. Derzeit ist sie Mitglied in den Aufsichtsräten mehrerer Gesundheitsunternehmen und hat einen Bachelor in Mikrobiologie von der University of Illinois sowie einen MBA von der Booth School of Business der University of Chicago.
- Appointment of Cynthia Collins, an experienced industry leader, to the Board of Directors
- Collins brings 40+ years of experience in biotechnology and cell and gene medicines
- Expansion of the Board to 10 members, potentially bringing more diverse expertise
- None.
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company’s Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board’s compensation committee. Following her appointment, MaxCyte’s total Board of Directors will increase to 10 members.
“I am pleased to welcome Cynthia to MaxCyte’s Board of Directors,” said Maher Masoud, President and CEO of MaxCyte. “Cynthia has extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years. I look forward to working alongside her to enable a growing set of next-generation cell therapies as the premier cell engineering platform in our industry.”
Ms. Collins brings over 40 years of experience in the biotechnology industry and cell and gene medicines to MaxCyte, including her most recent role as Chief Executive Officer of Editas Medicine, where she was involved in dosing the first patient ever with an in-vivo gene modified therapy. Previously, Ms. Collins served as Chief Executive Officer of Human Longevity Inc., Chief Executive Officer/General Manager of General Electric Healthcare’s Cell Therapy and Lab Businesses, and Chief Executive Officer of GenVec, Inc., a vaccine and gene therapy company.
Currently, Ms. Collins serves as a member of the Board of Directors of several healthcare companies, including Alanis Therapeutics, Nutcracker Therapeutics, Poseida Therapeutics (Nasdaq: PSTX), Certara (Nasdaq: CERT), DermTech (OTC: DMTKQ), Draper Laboratory, and Panavance Therapeutics. She is also a board member of the Foundation for mRNA Medicines.
Cynthia Collins holds a Bachelor of Science degree in Microbiology from the University of Illinois, Urbana and an MBA from The University of Chicago Booth School of Business.
“I am honored to join MaxCyte’s Board of Directors, where I believe there is exceptional work being done to propel the cell and genetic medicine industry forward,” said Cynthia Collins. “I am excited to support the Company’s growth and innovation as they continue to help developers bring a new class of therapies to market.”
Regulatory Disclosures
In accordance with Rule 17, Schedule Two paragraph (g) of the AIM Rules for Companies, Cynthia Lynne Collins (66) holds, or has held, the following directorship or partnerships in the last five years:
| Current | Past 5 years |
| Alanis Therapeutics, Inc. | Triumvira Immunologics, Inc. |
| Nutracker Therapeutics, Inc. | Biocare Medical LLC |
| Panavance Therapeutics, Inc. | Human Longevity, Inc. |
| The Charles Stark Draper Laboratory, Inc. | Editas Medicine, Inc. |
| Poseida Therapeutics, Inc. | ARM Foundation for Cell and Gene Medicine |
| Certara, Inc. | |
| DermTech Inc. | |
| The Foundation for MRNA Medicines, Inc. |
Cynthia Collins, was previously appointed as an independent director to the Board of DermTech, Inc. on May 24, 2018. On June 18, 2024, the Company filed for Chapter 11 bankruptcy. On August 21, 2024 the US Bankruptcy Court for the District of Delaware approved the sale of a substantial amount of DermTech Inc.’s assets through a court-supervised auction.
Save as disclosed above, there is no further information to be disclosed pursuant to Rule 17 Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the appointment of Cynthia Collins.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Science
Jordan Vines
jvines@spectrumscience.com
+1 540-629-3137
Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
FAQ
Who is Cynthia Collins and why was she appointed to MaxCyte's Board of Directors?
What positions has Cynthia Collins held prior to joining MaxCyte's Board?
How will Cynthia Collins' appointment affect MaxCyte's Board composition?
What is MaxCyte's stock symbol and where is it traded?
